With a second big clinical failure, Teva Pharmaceutical is abandoning efforts to extend the use of its approved migraine drug to the treatment of cluster headaches, a rarer form of headache that typically affects one side of the head around the eye or the temple.
Teva (NYSE: TEVA) said Tuesday that an interim analysis of a Phase 3 study found that its drug fremanezumab (Ajovy) was unlikely to reduce the average number of headache attacks over a four-week treatment period, the main goal of the study. As a result, the Israel-based company, which has US headquarters in Parsippany,… Read more »
UNDERWRITERS AND PARTNERS
